Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
6th Annual The Best of San Antonio: Breast Cancer—Bench to Bedside
Sheraton Chicago Hotel & Towers
Chicago, IL
February 7, 2009
Conference Overview
SAVE THE DATE!
Join us once again on the "Magnificent Mile" in downtown Chicago at the Sheraton Chicago Hotel & Towers.
The 6th Annual The Best of San Antonio: Breast Cancer—Bench to Bedside program is in the initial planning stages for 2009. The 2009 symposium, which will be chaired by Kathy Albain, MD, Loyola University Chicago, promises to be an extraordinary CME activity. Dr. Albain has invited a panel of nationally recognized key opinion leaders from the major breast cancer disciplines who will provide a critical review of the data presented at the 2008 San Antonio Breast Cancer Symposium.
Please mark your calendars now. Additional information with a formal agenda will follow. Due to the popularity of this symposium, we invite you to register today.
Coming soon!At the conclusion of this symposium, you should be able to:
- Identify and apply the most recent breast cancer treatment data from major international oncology meetings
- Identify advances in local therapy, including radiation therapy and surgery, for breast cancer
- Evaluate genomic and proteomic tools for the assessment of recurrence risk, prediction of benefit from chemotherapy, and individualization of therapeutic decision making
- Assess strategies for optimizing adjuvant chemotherapy for patients with breast cancer
- Discuss approaches for optimizing the use of adjuvant endocrine therapy, including duration and timing; the integration of bone-targeted agents into therapy; and the management of side effects
- Review chemotherapeutic and endocrine options for patients with metastatic breast cancer
- Evaluate the use of novel biologic agents, such as inhibitors of the angiogenic or HER/ErbB signaling pathways, as well as emerging targets in patients with advanced or metastatic breast cancer
- Discuss molecular translational research advances from both basic science and clinical perspectives
- Review information regarding currently available clinical trials of systemic treatments for breast cancer
Educational Grants
An educational grant for this activity was provided by:
- AstraZeneca
- Genentech BioOncology
- Genomic Health
- GlaxoSmithKline
- sanofi-aventis U.S.